The European Medicines Agency said Friday that its human medicines committee has adopted recommendations to increase manufacturing capacity and supply of Covid-19 vaccines in the European Union.
The agency said it has approved an increase in batch size and process scale-up at Pfizer Inc.'s manufacturing site in Puurs, Belgium, a move which is expected to have a "significant" impact on the supply of the vaccine it developed with BioNTech SE.
The agency's committee for medicinal products for human use also recommended the approval of a new filling line at Moderna Inc.'s manufacturing site in Rovi, Spain, the EMA said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.